NASDAQ$STTK
Shattuck Labs In · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Shattuck Labs reported no revenue and a net loss of $15.2 million for the second quarter ended June 30, 2026.
The company continued advancing its DR3-focused pipeline with SL-325 Phase 1 data showing favorable safety and receptor occupancy. Operating expenses rose to $16.2 million driven by clinical and preclinical activities. Cash and investments totaled $208.3 million providing runway into 2029.
- Revenue remained zero as the company is pre-commercial with all candidates in development.
- Net loss widened to $15.2 million from $12.5 million year-over-year due to higher R&D spend.
- Phase 1 data for SL-325 demonstrated complete receptor occupancy and low immunogenicity supporting quarterly dosing potential.
- Balance sheet strengthened with $153.8 million raised in equity financings during the first half of 2026.
Headline financials
Revenue & EPS history
Shattuck Labs · Revenue · Quarterly
$0
Forward guidance
Company plans to initiate Phase 2 trial of SL-325 in Crohn's disease in Q3 2026 with data expected in first half of 2028.
Tailwinds
- Strong cash position supports multiple clinical readouts
- Favorable Phase 1 immunogenicity and PK data for SL-325
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-2.3%
Avg return
Earnings day
-3.1%
Avg return
5 days after
-1.1%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+10.7%
Q2 2020
Best reaction
-34.2%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -6.4% | -0.9% | -31.6% | |
| Q4 2025 | +7.8% | +26.0% | +35.7% | |
| Q3 2025 | -4.5% | -2.9% | +52.0% | |
| Q1 2025 | -0.1% | -3.7% | +21.3% | |
| Q4 2024 | -7.0% | -13.7% | -30.2% | |
| Q3 2024 | +1.6% | -6.6% | -6.6% | |
| Q2 2024 | -8.3% | -22.4% | -9.8% | |
| Q1 2024 | -0.7% | -1.0% | -32.0% | |
| Q4 2023 | +7.3% | +6.3% | -0.6% | |
| Q3 2023 | -22.4% | -12.2% | +0.0% | |
| Q2 2023 | -10.7% | -11.1% | -9.1% | |
| Q1 2023 | +3.3% | -3.7% | +8.6% | |
| Q4 2022 | +4.8% | +8.5% | -30.3% | |
| Q3 2022 | -12.2% | -6.8% | -0.4% | |
| Q2 2022 | -2.8% | +1.3% | -17.3% | |
| Q1 2022 | +4.9% | -0.9% | +27.3% | |
| Q4 2021 | +10.3% | +22.4% | -13.1% | |
| Q3 2021 | -34.2% | -34.5% | -51.8% | |
| Q2 2021 | +1.2% | -1.5% | -1.4% | |
| Q1 2021 | -3.5% | -9.2% | -2.7% | |
| Q4 2020 | -2.5% | -13.8% | -13.3% | |
| Q3 2020 | +10.7% | +4.9% | +40.2% | |
| Q2 2020 | +10.7% | +4.9% | +40.2% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro